Table 1 Improving CAR-T potency
From: The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective
CAR-T ‘drug’ exposure | Cytokine support | Resistance to suppression |
|---|---|---|
Higher infused doses | IL-2 (in vivo) | Anticheckpoint Abs (PD1, PDL1, etc.) |
LD with engraftment | IL-15 (in vivo) | Anti-CTLA4 |
Higher-intensity LD | IL-12 (ex vivo) | CAR with 4-1BB |
IL-12 (in situ) | Treg depletion/anti-TGF-β | |
More signals (costimulation) | MDSC blockade | |
IDO inhibitors | ||
Stimulatory ligands (antigen-Fc) |
